IGFBP-2 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | 詳細 |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | 詳細 |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | 詳細 |
| Leronlimab | HuPRO-140; PA-14; PRO-140 | Phase 2 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Metabolic Dysfunction-Associated Steatotic Liver Disease; Rectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Triple Negative Breast Neoplasms; Colorectal Neoplasms | 詳細 |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Diabetic Nephropathies; Hyperplasia; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | 詳細 |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | 詳細 |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | 詳細 | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | 詳細 |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections; HIV Seropositivity | 詳細 |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Solid tumours; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colorectal Neoplasms; Lymphoma | 詳細 |
| OB-002 | OB-002; OB-002M; OB-002O; OB-002H; OB-002C; 5P12-RANTES; 5P12-RANTES-E66S | Phase 1 Clinical | Mintaka Medical Research Foundation | HIV Infections; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | HIV Infections; Acquired Immunodeficiency Syndrome; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hypertriglyceridemia; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; HIV Seropositivity; Sarcoma, Kaposi | 詳細 |